tbuckley/cabot-search huggingface dataset:
Incident rhinitis is related to dust and rye exposure among baker's apprentices
Authors: Torben Sigsgaard
Journal: European Respiratory Journal (2012)

Background: Baker's asthma and rhinitis are related to occupational exposure with an exposure-response relationship for prevalence and incidence. This study was a prospective study to estimate: The dose response relation between new onset asthma and rhinitis and the exposure to personal dust and allergens in baker apprentices during their apprenticeship.

Methods: Participants were recruited from baker schools. Baker apprentices without previous occupational exposure to flour, was followed for 1 (n=187) to 36 month (n=86).

They were examined every 4th month. Personal (n = 79) exposure to dust, rye- and wheat antigen were performed 1 or 2 times in each bakery. Cox proportional methods were used to estimate the hazard ratio (HR).

Results: We found 42 new cases of rhinitis and 27 of asthma like symptoms.

The dust and allergen levels were: dust Mean (SD) 1.9 (1.6), rye 0.8 (0.7) and wheat 0.8 (0.5) mg/m3.

The HR for high exposure to personal dust controlling for atopy was increased for rhinitis, table 1.

View this table:

Table 1. Cox proportional hazard modelling of Rhinitis with exposure





We found no association to wheat exposure, but for rye exposure an increased HR for rhinitis symptoms with exposure highest for the 3rd quartile, 2.9 (1.2-7.5) vs 1.6 (0.5-4.8) in the 4th quartile. Only 4 persons developed positive SPT to flour and two to α-amylase during the study.

Conclusions: In baker apprentices followed for 36 months, a dose dependent HR for rhinitis symptoms with exposure to to dust and rye antigen was seen.
A Prospective Study on TT Virus Infection in Transfusion-Dependent Patients With β-Thalassemia
Authors: Daniele Prati, Yu-Huei Lin, Claudia De Mattei, Jen-Kuei Liu, Elena Farma, Latha Ramaswamy, Alberto Zanella, Helen Lee, Paolo Rebulla, Jean-Pierre Allain, Girolamo Sirchia, Benjamin Chen
Journal: Blood (1999)
STUDIES ON THE PNEUMOCOCCUS
Authors: Frederick T. Lord, Robert N. Nye
Journal: The Journal of Experimental Medicine (1922)

Suspensions of living pneumococci in approximately isotonic standard solutions and in approximately isotonic bouillon with pH varying from about 4.0 to 8.0 after incubation show dissolution of organisms in those solutions having a pH higher than about 5.0. Dissolution is most marked at a critical range of about pH 5.0 to 7.0. Some dissolution also takes place toward the more alkaline end of the scale. No dissolution occurs at the most acid end of the scale. Dissolution in the standard solutions occurs at incubator, room, and ice box temperature. It is less marked at ice box temperature. Dissolution takes place in standard pH solutions with pneumococci allowed to grow and die out in glucose bouillon but unlike dissolution with living organisms is progressive from the acid toward the alkaline end of the scale. Pneumococci killed by heat for I hour undergo less dissolution than living organisms, the general character of the curve being similar to that with living organisms. Pneumococci killed by heat at 100 degrees C. for 5 minutes do not undergo dissolution. The addition of fresh human serum to the suspensions of pneumococci at varying pH prevents dissolution. Dissolution of pneumococci takes place more rapidly at pH 6.1 in standard solutions in which large numbers of pneumococci have been previously dissolved than in fresh standard solutions at the same pH. The dissolution of pneumococci under the conditions of the experiments may be ascribed to an enzyme derived from the bacteria themselves. Other organisms such as Streptococcus viridans and hoemolyticus and Staphylococcus aureus do not undergo dissolution under conditions similar to those to which the pneumococcus was exposed.
Characterization of a Cell Line Derived From the Ascites of a Patient With Papillary Serous Cystadenocarcinoma of the Ovary&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: A P Wilson
Journal: JNCI Journal of the National Cancer Institute (1984)

Journal Article Characterization of a Cell Line Derived From the Ascites of a Patient With Papillary Serous Cystadenocarcinoma of the Ovary Get access Anne P. Wilson Anne P. Wilson Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 72, Issue 3, March 1984, Pages 513–521, https://doi.org/10.1093/jnci/72.3.513 Published: 01 March 1984 Article history Received: 14 January 1983 Revision received: 10 October 1983 Accepted: 28 October 1983 Published: 01 March 1984
First step in the development of an ultrasound joint inflammation score for rheumatoid arthritis using a data-driven approach
Authors: Anna-Birgitte Aga, Hilde Berner Hammer, Inge Christoffer Olsen, Till Uhlig, Tore K Kvien, Désirée van der Heijde, Hallvard Fremstad, Tor Magne Madland, Åse Stavland Lexberg, Hilde Haukeland, Erik Rødevand, Christian Høili, Hilde Stray, Anne Noraas Bendvold, Dag Magnar Soldal, Gunnstein Bakland, Elisabeth Lie, Espen A Haavardsholm
Journal: Annals of the Rheumatic Diseases (2015)

To develop and validate candidate sets of joints and tendons for assessment of ultrasound (US) joint inflammation in rheumatoid arthritis (RA).Patients were included in one of two cohorts from 2010 to June 2013: disease-modifying antirheumatic drug naïve early RA or established RA starting/switching biologics. An extensive US examination was performed by experienced sonographers using a validated grey-scale (GSUS) and power Doppler (PDUS) semiquantitative scoring system with scores 0-3 for both GSUS and PDUS in 36 joints and four tendons. We performed factor analysis in the early RA US data and selected candidate joint/tendon sets based on these results. The proportion of information in the total US scores retained in these candidate sets was assessed by R(2) from linear regression analysis. Finally, the candidate sets and previously proposed joint scores were tested in the established RA cohort, and we also evaluated the sensitivity to change with standardised response means.227 patients with early RA and 212 patients with established RA were included. We identified two candidate sets of joints/tendons: candidate set A consisted of seven joints/two tendons (meatacarpophalangeal 1 (MCP1), MCP2, proximal interphalangeal 3, radiocarpal, elbow, metatarsophalangeal 1 (MTP1), MTP2, tibialis posterior tendon, extensor carpi ulnaris tendon) and set B of nine joints/two tendons (MCP5 and MTP5 added to set A). Unilateral reduced scores retained 78%-85% of the information in total score, while bilateral reduced scores retained 89%-93%, and both sets performed better than previously proposed reduced joint scores, and similar or slightly better regarding sensitivity to change.The reduced GSUS and PDUS scores retained most of the information from the total score and performed well in a validation cohort of established RA.NCT01205854, ACTRN12610000284066.
Retraction Note: A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function
Authors: Sonia A Melo, Santiago Ropero, Catia Moutinho, Lauri A Aaltonen, Hiroyuki Yamamoto, George A Calin, Simona Rossi, Agustin F Fernandez, Fatima Carneiro, Carla Oliveira, Bibiana Ferreira, Chang-Gong Liu, Alberto Villanueva, Gabriel Capella, Simo Schwartz, Ramin Shiekhattar, Manel Esteller
Journal: Nature Genetics (2016)
Long-Term Outcomes of Abdominal Aortic Aneurysm in the Medicare Population
Authors: Marc L. Schermerhorn, Dominique B. Buck, A. James O’Malley, Thomas Curran, John C. McCallum, Jeremy Darling, Bruce E. Landon
Journal: New England Journal of Medicine (2015)

Randomized trials and observational studies have shown that perioperative morbidity and mortality are lower with endovascular repair of abdominal aortic aneurysm than with open repair, but the survival benefit is not sustained. In addition, concerns have been raised about the long-term risk of aneurysm rupture or the need for reintervention after endovascular repair.
High frequency of human leucocyte antigen (HLA) A2 reflects a poorer prognosis in a group of advanced ovarian cancer patients
Authors: K. Bergfeldt, C. Hising, Z. Gamzatova, B. Tholander, E. Åvall-Lundqvist, H. G. M. van der Zanden, G. Masucci
Journal: Journal of Clinical Oncology (2005)

5054 Background: Immune escape mechanisms depend on alterations in the expression of major histocompatibility complex (MHC) molecules and are known to be of importance in tumor development. According to epidemiological data the frequency of HLA-A2 in Europe is correlated with ovarian cancer mortality, that is, HLA-A2 frequency as well as ovarian cancer mortality rates are high in the northern parts (Scandinavia) and substantially lower in the south. We have recently characterized a group of ovarian cancer patients with a high frequency of HLA-A2 phenotype. We further analyzed the incidence of A2 homozygotes and haplotypes related to clinical parameters, together with survival associated to HLA-A2. Methods: 28 unrelated patients initially diagnosed with advanced ovarian cancer (stage III and IV) with relapsing or progressive disease were analysed for the genotypes at HLA-A, -B, -C, and -DRB1 loci, by PCR/sequence-specific oligonucleotide hybridization. As comparison, we used the frequencies of HLA alleles in healthy Swedish bone marrow donors, provided by the coordinating centre of the Bone Marrow Donors Worldwide Registries, Leiden, The Netherlands. Results: The frequency of the HLA-A2 genotype was 46% among the ovarian cancer patients compared to the healthy Swedish population: 35%). The A3 allele was poorly represented (12% vs. 17%). Seven patients were homozygotes for A2 allele (25%), which is two times the healthy Swedish population (12%), and three times the median frequency in Europe (8%). We also observed an increase in several A2 + B- and DRB1 haplotypes. Median overall survival among HLA-A2 positive patients were 2.6 years (min1.5 - max 6.2) versus 3.1 in non-A2-patients (min 1.3 - max 8.7). A2-heterozygotes (n=12) were found with a median survival of 2.5 years (min 1.4 - max 3.7). Conclusions: Our findings indicate that there is an unusual overrepresentation of the HLA-A2 allele in a group of ovarian cancer patients with a poor prognosis and clinical history. Further investigations are warranted to establish if the negative prognostic correlation with HLA-A2 can be reproduced in other ovarian cancer populations. No significant financial relationships to disclose.
Effects of two chest physiotherapy protocols on lung mechanics and cardiorespiratory parameters in the mechanically ventilated patients
Authors: Fernanda Klose Preuss, Fernanda Vianna Schmitt, Janice Cristina Soares, Isabella Martins de Albuquerque, Maria Elaine Trevisan
Journal: European Respiratory Journal (2014)

Background: There is limited evidence to support the use of ventilator hyperinflation by physiotherapists working in intensive care units. Even fewer studies have compared ventilator hyperinflation with the vibrocompression.  Objective: To compare the effects of two chest physiotherapy protocols on lung mechanics and cardiorespiratory parameters in patients undergoing mechanical ventilation.  Methods: A quasi-experimental study that included 50 critical patients (mean age 55,6±15,3 years old) who were receiving mechanical ventilation for more than 48 hours.The subjects were allocated into three groups: aspiration (control, n=16); vibrocompression and aspiration (n=17); vibrocompression, aspiration and ventilator hyperventilation (n=17). Heart rate, respiratory rate, blood pressure, oxygen saturation, static and dynamic lung compliance, and airway resistance were measured and compared between three groups before (baseline), immediately after and 15 minutes after the end of each protocol. For statistical analysis were used, Shapiro-Wilk test and one-way ANOVA with the  post - hoc Bonferroni  test (p≤0.05).  Results: There were no significant differences in the lung mechanics and cardiorespiratory parameters between the 3 periods (before, immediately after and 15 minutes after the end of each protocol) endotracheal suctioning) into the groups.  Conclusions: Chest physiotherapy can be safely on patients undergoing mechanical ventilation, although this study suggests that the use of ventilator hyperinflation isolated or associated vibrocompression does not improve lung mechanics in this population of mechanically ventilated patients.
Development of a multicomponent vaccine for Streptococcus pyogenes based on the antigenic targets of IVIG
Authors: Mark Reglinski, Nicola N. Lynskey, Yoon Jung Choi, Robert J. Edwards, Shiranee Sriskandan
Journal: Journal of Infection (2016)

ObjectivesDespite over a century of research and the careful scrutiny of many promising targets, there is currently no vaccine available for the prevention of Streptococcus pyogenes infection. Through analysis of the protective, anti-streptococcal components of pooled human immunoglobulin, we previously identified ten highly conserved and invariant S. pyogenes antigens that contribute to anti-streptococcal immunity in the adult population. We sought to emulate population immunity to S. pyogenes through a process of active vaccination, using the antigens targeted by pooled human immunoglobulin.MethodsSeven targets were produced recombinantly and mixed to form a multicomponent vaccine (Spy7). Vaccinated mice were challenged with S. pyogenes isolates representing four globally relevant serotypes (M1, M3, M12 and M89) using an established model of invasive disease.ResultsVaccination with Spy7 stimulated the production of anti-streptococcal antibodies, and limited systemic dissemination of M1 and M3 S. pyogenes from an intramuscular infection focus. Vaccination additionally attenuated disease severity due to M1 S. pyogenes as evidenced by reduction in weight loss, and modulated cytokine release.ConclusionSpy7 vaccination successfully stimulated the generation of protective anti-streptococcal immunity in vivo. Identification of reactive antigens using pooled human immunoglobulin may represent a novel route to vaccine discovery for extracellular bacteria.
Photocarcinogenesis and Influence of UV Radiation on Autoimmune Disease in NZB/N Mice234
Authors: Paul T. Strickland
Journal: JNCI Journal of the National Cancer Institute (1984)

Several biologic effects of UV radiation on NZB/N mice were studied. NZB mice exhibited normal susceptibility to photocarcinogenesis compared to another pigmented but nonautoimmune mouse strain, C57BL/6NCr. Susceptibility was compared on the basis of latency, anatomic location, and histologic type of tumors induced by chronic UV irradiation. The influence of UV irradiation on progression of spontaneous autoimmune disease in NZB mice was examined with respect to anti-DNA antibodies, excretion of protein in urine, survival, glomerulo-nephritis, and leukemia. UV irradiation of NZB mice reduced both survival of mice and the level of serum antibody binding to DNA. Reduced survival occurred not only in autoimmune mice but also in C57BL/6 mice. Serum antibody binding to single-stranded DNA (ssDNA) was reduced in UV-irradiated NZB mice compared to that in untreated NZB mice, but it recovered to normal (untreated) levels after termination of UV irradiation. No alteration in preference of DNA antibodies for ssDNA, UVssDNA, doublestranded DNA (dsDNA), or UVdsDNA was observed in UV-irradiated mice.
Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126
Authors: H. West, W. A. Franklin, P. H. Gumerlock, R. B. Vance, D. H. M. Lau, J. McCoy, J. Crowley, D. R. Gandara
Journal: Journal of Clinical Oncology (2004)

7014 Background: BAC, a non-small cell lung cancer (NSCLC) subtype with distinctive clinical, pathologic, and radiographic characteristics, is increasing in incidence, especially among younger non-smoking women. Based on analysis of EGFR pathway expression patterns in BAC specimens from the SWOG Lung repository (Franklin, ASCO 2003) and anecdotal reports of prolonged complete response (CR) of advanced stage BAC to gefitinib, SWOG initiated S0126 to determine potential clinical, radiographic, pathologic, and molecular markers predictive of outcome under the influence of gefitinib therapy. Methods: 138 eligible patients (102 chemo-naive, 36 previously treated) were enrolled. Gefitinib 500 mg PO QD was given until evidence of progression or prohibitive toxicity. Results: Median age: 68.0 (range 34.3–88.6); 51% female; PS 0/1: 86%. Among 67 chemo-naive patients with measurable disease, the response rate (RR) by RECIST is 21%, with 6% CR. In 21 previously treated patients with measurable disease, RR is 10% (0% CR). Data on response by computer assisted image analysis will be presented. Median survival is 12 and 10 months for chemo-naïve and previously treated patients, respectively (p=NS). One year survival is ∼50% in each subgroup. Toxicity: acneiform rash and diarrhea as previously described; potential grade 5 toxicity in three cases of patients with increasing pulmonary consolidation, possible interstitial lung disease secondary to treatment versus disease progression and/or infection. Subset analyses show prolonged survival in females (16 vs 7 months, p=.003) and patients with rash (12 vs 5 months, p=.01). For molecular correlative studies, see Franklin: ASCO 04. Conclusions: 1) Gefitinib demonstrates single-agent activity in advanced BAC in both chemo-naïve and previously treated patients; 2) S0126 represents a large clinical and pathologic database of BAC, and as such is a resource for improving understanding of this unique NSCLC subset; 3) Further studies of EGFR inhibitors in BAC are warranted. (CA32102, CA38926) Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca AstraZeneca AstraZeneca Southwest Oncology Group
High Response Rate To Combination Lenalidomide-Rituximab In FcγRIIIa-F Carriers With Indolent Or Mantle Cell Lymphomas Previously Refractory To Rituximab
Authors: Elise A. Chong, Tahamtan Ahmadi, Nicole A. Aqui, Sunita D. Nasta, Jakub Svoboda, Kristy M. Walsh, Amanda Gordon, Stephen J. Schuster
Journal: Blood (2013)
Discharge criteria for Crimean–Congo haemorrhagic fever in endemic areas
Authors: Hakan Leblebicioglu, Mustafa Sunbul, Hurrem Bodur, Resat Ozaras, Sener Barut, Seyit Ali Buyuktuna, Rahmet Guner, Zulal Ozkurt, Gonul Cicek Senturk, Derya Yapar, Gurdal Yilmaz
Journal: Journal of Infection (2016)
Dose finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors
Authors: E. Donato Di Paola, S. Alonso, A. D’Alessio, R. Giuliani, F. Calabrò, C. Messina, A. Zivi, E. Squilloni, S. De Marco, C. Sternberg
Journal: Journal of Clinical Oncology (2009)

e13534 Background: The potential advantage of combining satraplatin (S) a novel oral platinum with Gem is attractive. MTD and DLT of combination S and Gem in patients (pts) with advanced solid tumors was evaluated. Methods: Cohorts of 3–6 pts (modified Fibonacci) received escalating doses of i.v. Gem on days (d) 1, 8 and 15 Q 28 d followed by oral S on d 1–5. Seventeen pts with metastatic solid tumors were separated into 2 groups: A) Pts that had progressed following cytotoxic therapy and B) Pts who had received no prior chemotherapy. Starting dose was Gem 800 mg in both groups, S 40 mg and 60 mg for A and B respectively. Results: Group A. 6 previously treated pts with 1 or 2 regimens (3 prostate, 1 hepatocarcinoma, 1 bladder and 1 thymic ca) received 25 cycles, median 2 (2–12). 2 DLTs (G3 transaminases) were observed in 6 pts treated at level 1. Other G3 major toxicities were: thrombocytopenia (1 pt) and diarrhea (1 pt). 2 pts had PSA declines, with TTP of 630 days in 1 of them. Group B. 11 pts with no prior chemotherapy (4 hepatocarcinoma, 4 pancreas, 1 renal, 1 unknown origin and 1 gallbladder), received 38 cycles, median 2 (1–12). 1 DLT (G3 diarrhea) was observed in 8 pts treated at level 1 (2 not evaluable; received Gem d1 only), DLT (G3 thrombocytopenia) was observed in 3 pts treated at level 2 (Gem 1000, S 60). Other G3 toxicities were: thrombocytopenia (3 pts) and neutropenia (3 pts). 1 CR (pancreas) and 1 PR (gallbladder) were observed. Gem d8 or d15 was omitted in 11 of 17 pts during the 1st cycle. Conclusions: In this study the combination of S and Gem showed a clinically acceptable toxicity profile with promising antitumor activity. However, since in cycle 1, it was not possible to administer Gem on both d8 and d15 on 11 occasions, a 2 nd study was initiated with S d1–3 and Gem d1 and 8 given on a Q 21 d schedule. Sponsored by GPC Biotech No significant financial relationships to disclose.
A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease
Authors: D. A. Cameron, E. Winer, S. Campos, J.-P. Guastalla
Journal: Journal of Clinical Oncology (2004)

628 Background: A pilot, open-label, multicenter, multinational, randomized, parallel group, comparative study was conducted in post-menopausal women with advanced ER/PgR + breast cancer (BC) and at least one visceral lesion (liver or lung) measurable using RECIST criteria Methods: Subjects had progressed during prior antiestrogen treatment, or ≤ 12 months since adjuvant antiestrogen treatment. Subjects were randomized 1:1 to either exemestane (E) (25 mg po qd) or anastrozole (A) (1 mg po qd). Prior treatment with ≤ chemotherapy (CT) regimen for metastatic BC was permitted. ECOG performance status of 0 –2. Primary efficacy end-point was objective response rate in visceral disease using modified RECIST Guidelines. Stable disease required documentation over 24 weeks. Secondary end-points included tolerability (absence of NCI CTC grade 2 –4 AEs), TTP, and survival. Results: The last patient was enrolled 20Dec2002. 28 patients remained on study drug as of 1Nov2003. Data are shown in the Table. There are no significant differences in efficacy between the two agents. Grade 3 + 4 toxicities of interest looked similar across arms and include hot flashes in 2 (E) and 4 (A) patients, musculoskeletal complaints in 2 (E) and 1 (A). Conclusions: On the basis of this study, since 40% of the patients had a response or stable disease for at least 6 months, aromatase inhibitors/inactivators appear to be a suitable choice of therapy for patients with visceral metastatic disease from breast cancer following antiestrogen therapy. The toxicity profile of E and A were similar over the duration of this study treatment. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Pfizer; Pharmacia/Pfizer Pfizer; Pharmacia/Pfizer AstraZeneca